1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Drugs In Development, 2022, provides an overview of the Cataract (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Cataract - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cataract (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Cataract (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cataract (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cataract (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cataract (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cataract (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cataract (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Cataract - Overview
- Cataract - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cataract - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cataract - Companies Involved in Therapeutics Development
- Calpain Therapeutics Pty Ltd
- Caregen Co Ltd
- Cellix Bio Pvt Ltd
- CGeneTech (Suzhou China) Co Ltd
- Genisphere LLC
- Kubota Vision Inc
- Nacuity Pharmaceuticals Inc
- Optus Pharmaceutical Co Ltd
- Plex Pharmaceuticals Inc
- Reven Holdings Inc
- ViewPoint Therapeutics Inc
- Vitreo Pharma Inc
- Cataract - Drug Profiles
- CAP-1160 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CAP-4196 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CAT-811 - Drug Profile
- Product Description
- Mechanism Of Action
- Cataract - Drug Profile
- Product Description
- Mechanism Of Action
- CGT-1507 - Drug Profile
- Product Description
- Mechanism Of Action
- CLXOPH-65 - Drug Profile
- Product Description
- Mechanism Of Action
- DHPNP-06 - Drug Profile
- Product Description
- Mechanism Of Action
- GL-249 - Drug Profile
- Product Description
- Mechanism Of Action
- NPI-002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RPEC-1007a - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Presbyopia and Cataract - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit NFkB for Ophthalmology, Oncology, Dermatology, Immunology and Infectious Disease - Drug Profile
- Product Description
- Mechanism Of Action
- tafamidis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VP-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VT-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- ZOC-2017217 - Drug Profile
- Product Description
- Mechanism Of Action
- Cataract - Dormant Projects
- Cataract - Discontinued Products
- Cataract - Product Development Milestones
- Featured News & Press Releases
- May 01, 2018: ViewPoint Appoints Dr. Robert Kim as Chief Medical Officer
- Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts
- May 13, 2012: Calpain Therapeutics Wins Commercialisation Australia Grant To Progress Anti-Cataract Programme
- Sep 04, 2011: New Drug Eyes Way To Beat Cataracts
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Cataract, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Cataract - Pipeline by Calpain Therapeutics Pty Ltd, 2022
- Cataract - Pipeline by Caregen Co Ltd, 2022
- Cataract - Pipeline by Cellix Bio Pvt Ltd, 2022
- Cataract - Pipeline by CGeneTech (Suzhou China) Co Ltd, 2022
- Cataract - Pipeline by Genisphere LLC, 2022
- Cataract - Pipeline by Kubota Vision Inc, 2022
- Cataract - Pipeline by Nacuity Pharmaceuticals Inc, 2022
- Cataract - Pipeline by Optus Pharmaceutical Co Ltd, 2022
- Cataract - Pipeline by Plex Pharmaceuticals Inc, 2022
- Cataract - Pipeline by Reven Holdings Inc, 2022
- Cataract - Pipeline by ViewPoint Therapeutics Inc, 2022
- Cataract - Pipeline by Vitreo Pharma Inc, 2022
- Cataract - Dormant Projects, 2022
- Cataract - Discontinued Products, 2022
- Number of Products under Development for Cataract, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Calpain Therapeutics Pty Ltd
- Caregen Co Ltd
- Cellix Bio Pvt Ltd
- CGeneTech (Suzhou China) Co Ltd
- Genisphere LLC
- Kubota Vision Inc
- Nacuity Pharmaceuticals Inc
- Optus Pharmaceutical Co Ltd
- Plex Pharmaceuticals Inc
- Reven Holdings Inc
- ViewPoint Therapeutics Inc
- Vitreo Pharma Inc
